TheraRadar
← Back
Data updated: Jun 28, 2026

EISAI INC

Big Pharma
OncologyNeurologyGastroenterology Execution: Excellent

EISAI INC is a major pharmaceutical company focused on Oncology, Neurology, Gastroenterology. Key products include LENVIMA.

1990
Since
11
Drugs
-
Trials
1
New Drugs (2yr)
Modality:
5 Small Molecules 1 Biologics

FDA Novel Drug Designations

(2019-2023)
2 Novel 1 Breakthrough 1 Accelerated 1 Priority Review 1 Fast Track
See 2 novel approvals →
2023 LEQEMBI (LECANEMAB-IRMB) Breakthrough · Priority Review · Accelerated · Fast Track
2019 DAYVIGO (LEMBOREXANT)

EISAI INC at a Glance

  • Strong track record with 93% execution quality across 106 trials
  • Fast trial execution (25 months median completion)

EISAI INC's Recent FDA Approvals

EISAI INC secured 1 new FDA approval for novel drugs (NDA/BLA) in the last two years.

LEQEMBI IQLIK BLA
2025-08-29
lecanemab-irmb
Alzheimer's Disease

EISAI INC's Therapeutic Areas

EISAI INC's approved drugs and pipeline span 5 therapeutic areas, led by Oncology and Neurology, across 1 biologic and 5 small-molecule drugs. Weighted by commercial stage — approved drugs count most, then late-stage trials.

Oncology 47%
3 drugs Phase 3: 7 Phase 2: 26 Phase 1: 40
Neurology 34%
4 drugs Phase 3: 10 Phase 2: 11 Phase 1: 15
Gastroenterology 10%
0 drugs Phase 3: 6 Phase 1: 4
Metabolic 9%
1 drugs Phase 3: 2 Phase 2: 3 Phase 1: 6
Respiratory 0%
0 drugs Phase 1: 1

EISAI INC's Top Competitors

EISAI INC's closest competitors by therapeutic-area and drug-target overlap include Merck, AZURITY, and Johnson & Johnson. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.

Merck big-pharma
Oncology, Metabolic, Respiratory
AZURITY specialty
Oncology, Neurology, Metabolic, Respiratory
Johnson & Johnson big-pharma
Oncology, Gastroenterology, Metabolic
EMD SERONO biotech
Oncology, Neurology, Metabolic, Gastroenterology
GSK big-pharma
Respiratory, Oncology, Metabolic

EISAI INC Pipeline Snapshot

EISAI INC has 131 active clinical programs from ClinicalTrials.gov — 25 Phase 3, 40 Phase 2 and 66 Phase 1.

25
Phase 3
40
Phase 2
66
Phase 1

Phase 3 Readout Calendar Pro

2 Phase 3 trials with confidence-graded primary completion dates.

Full calendar →
Q4 2028
Lecanemab
Preclinical Alzheimer's Disease
Estimated · fresh NCT04468659
Q2 2029
Lecanemab IV
Early Alzheimer's Disease
Estimated · fresh NCT03887455

Anchored on CT.gov primary completion date. Topline announcements typically precede this by 3–9 months. Confidence labels combine date type (ACTUAL/ESTIMATED) with last-update freshness.

Pro Intelligence Preview

Deep insights for investors and analysts

Revenue Insights

  • • LENVIMA leads revenue
  • • 4 key drugs tracked
View revenue breakdown →

Trial Catalysts

  • • Oncology pipeline focus
  • • 2 Phase 3 readouts tracked
View readout calendar →

Patent Risk

  • • Patent expiration timeline
  • • Revenue at risk analysis
View patent timeline →

Compare Companies

  • • Side-by-side pipeline analysis
  • • Revenue & market share comparison
Compare with competitor →

Execution Intelligence

  • • Phase 3: 17/18 completed
  • • Speed: 25 months avg
Unlock Full Intelligence

Revenue forecasts • Trial milestones • Patent risk modeling

How We Calculate These Metrics

Execution Quality Score

Measures trial completion rates weighted by phase importance. Phase 3 trials count 4x more than Phase 1 because late-stage completion is harder and more valuable.

What counts as "completed": A trial that reached its planned endpoint and reported results. Trials that were terminated early, withdrawn, or suspended are not counted as completed—these often indicate safety issues, lack of efficacy, or strategic pivots.

  • Excellent (80%+): Top-tier execution, most trials reach planned endpoints
  • Good (60-79%): Strong execution with occasional early terminations
  • Fair (40-59%): Average execution, notable rate of terminated/withdrawn trials
  • Needs Improvement (under 40%): High termination rates, execution challenges